Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis.

Literature DB >> 22935588

Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis.

Marc E Rothenberg, Seema Aceves, Peter A Bonis, Margaret H Collins, Nirmala Gonsalves, Sandeep K Gupta, Ikuo Hirano, Chris A Liacouras, Phil E Putnam, Jonathan M Spergel, Alex Straumann, Barry K Wershil, Glenn T Furuta.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2012 PMID： 22935588 PMCID： PMC3828675 DOI： 10.1016/j.jaci.2012.06.051

Source DB: PubMed Journal: J Allergy Clin Immunol ISSN： 0091-6749 Impact factor: 10.793

× No keyword cloud information.

9 in total

1. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.

Authors: Ranjan Dohil; Robert Newbury; Lyman Fox; John Bastian; Seema Aceves
Journal: Gastroenterology Date: 2010-05-07 Impact factor: 22.682

2. Placebo and other interventions in asthma.

Authors: Alex Straumann; Ekaterina Safroneeva; Alain M Schoepfer
Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245

3. Active albuterol or placebo, sham acupuncture, or no intervention in asthma.

Authors: Michael E Wechsler; John M Kelley; Ingrid O E Boyd; Stefanie Dutile; Gautham Marigowda; Irving Kirsch; Elliot Israel; Ted J Kaptchuk
Journal: N Engl J Med Date: 2011-07-14 Impact factor: 91.245

Review 4. Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies.

Authors: Joseph D Sherrill; Marc E Rothenberg
Journal: J Allergy Clin Immunol Date: 2011-05-13 Impact factor: 10.793

5. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.

Authors: Michael R Konikoff; Richard J Noel; Carine Blanchard; Cassie Kirby; Sean C Jameson; Bridget K Buckmeier; Rachel Akers; Mitchell B Cohen; Margaret H Collins; Amal H Assa'ad; Seema S Aceves; Philip E Putnam; Marc E Rothenberg
Journal: Gastroenterology Date: 2006-08-16 Impact factor: 22.682

Review 6. Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors: Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal: J Allergy Clin Immunol Date: 2011-04-07 Impact factor: 10.793

Review 7. Patient-reported outcomes to support medical product labeling claims: FDA perspective.

Authors: Donald L Patrick; Laurie B Burke; John H Powers; Jane A Scott; Edwin P Rock; Sahar Dawisha; Robert O'Neill; Dianne L Kennedy
Journal: Value Health Date: 2007 Nov-Dec Impact factor: 5.725

Review 8. The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature.

Authors: J M Valderas; A Kotzeva; M Espallargues; G Guyatt; C E Ferrans; M Y Halyard; D A Revicki; T Symonds; A Parada; J Alonso
Journal: Qual Life Res Date: 2008-01-04 Impact factor: 4.147

9. Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases.

Authors: Robert Fiorentino; Gumei Liu; Anne R Pariser; Andrew E Mulberg
Journal: J Allergy Clin Immunol Date: 2012-07-31 Impact factor: 10.793

9 in total

24 in total

1. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis.

Authors: Bridget K Butz; Ting Wen; Gerald J Gleich; Glenn T Furuta; Jonathan Spergel; Eileen King; Robert E Kramer; Margaret H Collins; Emily Stucke; Colleen Mangeot; W Daniel Jackson; Molly O'Gorman; J Pablo Abonia; Scott Pentiuk; Philip E Putnam; Marc E Rothenberg
Journal: Gastroenterology Date: 2014-04-22 Impact factor: 22.682

Review 2. A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis.

Authors: Evan S Dellon; Sandeep K Gupta
Journal: Clin Gastroenterol Hepatol Date: 2019-01-30 Impact factor: 11.382

Review 3. White Paper AGA: Drug Development for Eosinophilic Esophagitis.

Authors: Ikuo Hirano; Stuart Spechler; Glenn Furuta; Evan S Dellon
Journal: Clin Gastroenterol Hepatol Date: 2017-03-22 Impact factor: 11.382

4. Management of eosinophilic esophagitis from childhood to adulthood.

Authors: Glenn T Furuta
Journal: Gastroenterol Hepatol (N Y) Date: 2012-10

5. Eosinophilic esophagitis: historical perspective on an evolving disease.

Authors: Stephen E Attwood; Glenn T Furuta
Journal: Gastroenterol Clin North Am Date: 2014-03-24 Impact factor: 3.806

Review 6. Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis.

Authors: Ikuo Hirano; Seema S Aceves
Journal: Gastroenterol Clin North Am Date: 2014-04-16 Impact factor: 3.806

7. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.

Authors: Doerthe A Andreae; Matthew G Hanna; Margret S Magid; Stefano Malerba; Michael H Andreae; Emilia Bagiella; Mirna Chehade
Journal: Am J Gastroenterol Date: 2016-06-21 Impact factor: 10.864